darakd Search Results


darakd  (CANDOR Bioscience)
90
CANDOR Bioscience darakd
Landmark trials in multiple myeloma.
Darakd, supplied by CANDOR Bioscience, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/darakd/pmc08657274-26-5-0?v=CANDOR+Bioscience
Average 90 stars, based on 1 article reviews
darakd - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
daratumumab plus carfilzomib and dexamethasone  (CANDOR Bioscience)
90
CANDOR Bioscience daratumumab plus carfilzomib and dexamethasone
Landmark trials in multiple myeloma.
Daratumumab Plus Carfilzomib And Dexamethasone, supplied by CANDOR Bioscience, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/darakd/pm36612152-39-5-11?v=CANDOR+Bioscience
Average 90 stars, based on 1 article reviews
daratumumab plus carfilzomib and dexamethasone - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
darak aprel  (Aprel Laboratories)
90
Aprel Laboratories darak aprel
Landmark trials in multiple myeloma.
Darak Aprel, supplied by Aprel Laboratories, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/darakd/10__1162_slash_octo_a_00366-85-23-24?v=Aprel+Laboratories
Average 90 stars, based on 1 article reviews
darak aprel - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
wetzlar orthoplan microscope  (Leitz GmbH)
90
Leitz GmbH wetzlar orthoplan microscope
Landmark trials in multiple myeloma.
Wetzlar Orthoplan Microscope, supplied by Leitz GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/darakd/10__1016_slash_j__culher__2018__09__018-75-11-24?v=Leitz+GmbH
Average 90 stars, based on 1 article reviews
wetzlar orthoplan microscope - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
edaradd human qpcr template standard  (OriGene)
N/A
qPCR primer pairs and template standards against Homo sapiens gene EDARADD
   Buy from Supplier
edaradd antibody (fitc)  (biorbyt)
N/A
Rabbit polyclonal antibody against EDARADD conjugated to FITC Isotype Note: IgG Host Note: Rabbit Conjugation Note: FITC Reactivity Note: Human, Mouse, Rat Application Note: IF/ICC
   Buy from Supplier
edaradd mouse qpcr primer pair  (OriGene)
N/A
qSTAR qPCR primer pairs against Mus musculus gene Edaradd
   Buy from Supplier
edaradd human shrna lentiviral particle  (OriGene)
N/A
EDARADD Human shRNA lentiviral particles 4 unique 29mer target specific shRNA 1 scramble control 0 5 ml each 10 7 TU ml
   Buy from Supplier
edaradd cytosection  (OriGene)
N/A
Transient overexpression of EDARADD NM 080738 in HEK293T cells paraffin embedded 4 um sections controls for ICC IHC staining 5 slides per pack
   Buy from Supplier
edaradd nm 080738 human tagged orf clone  (OriGene)
N/A
EDARADD GFP tagged Human EDAR associated death domain EDARADD transcript variant B
   Buy from Supplier
edaradd nm 145861 human tagged orf clone lentiviral particle  (OriGene)
N/A
Lenti ORF particles EDARADD mGFP tagged Human EDAR associated death domain EDARADD transcript variant A 200ul 10 7 TU mL
   Buy from Supplier

Image Search Results


Landmark trials in multiple myeloma.

Journal: Cancers

Article Title: Stratification for RRMM and Risk-Adapted Therapy: Sequencing of Therapies in RRMM

doi: 10.3390/cancers13235886

Figure Lengend Snippet: Landmark trials in multiple myeloma.

Article Snippet: CANDOR 2020 [ ] , DaraKd vs. Kd , 3 , 312 vs. 154 , 29% * , Refractory to bortezomib or ixazomib HR 0.84 (0.52–1.36).

Techniques:

Recent trials including patients refractory to prior therapy lines.

Journal: Cancers

Article Title: Stratification for RRMM and Risk-Adapted Therapy: Sequencing of Therapies in RRMM

doi: 10.3390/cancers13235886

Figure Lengend Snippet: Recent trials including patients refractory to prior therapy lines.

Article Snippet: CANDOR 2020 [ ] , DaraKd vs. Kd , 3 , 312 vs. 154 , 29% * , Refractory to bortezomib or ixazomib HR 0.84 (0.52–1.36).

Techniques: Clinical Proteomics

Response rates of recent landmark trials according to cytogenetic risk status.

Journal: Cancers

Article Title: Stratification for RRMM and Risk-Adapted Therapy: Sequencing of Therapies in RRMM

doi: 10.3390/cancers13235886

Figure Lengend Snippet: Response rates of recent landmark trials according to cytogenetic risk status.

Article Snippet: CANDOR 2020 [ ] , DaraKd vs. Kd , 3 , 312 vs. 154 , 29% * , Refractory to bortezomib or ixazomib HR 0.84 (0.52–1.36).

Techniques: